Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab + BMS986205 for Head and Neck Cancer
Recruiting1 awardPhase 2
Columbus, Ohio
This trial studies nivolumab with or without BMS986205 to treat patients with squamous cell cancer of the head and neck. Nivolumab is an immunotherapy that may help the body's immune system attack the cancer. BMS986205 is a drug that may stop the growth of tumor cells. Giving nivolumab with BMS986205 may work better than nivolumab alone.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.